TherapeuticsMD raises $15M from Rubric, extends debt maturity to Sept 2022

TherapeuticsMD, Inc.

Issued 15,000 Series A Preferred ($1,000 stated value) and 565,000 common shares to Rubric for $15M gross proceeds.
Rubric owns ~18.3% of common stock post-closing; Series A has $1,333/share liquidation preference and matures Dec 31, 2022.
Financing Agreement with Sixth Street extended to Sept 30, 2022; can extend to Nov 30 if $7M additional equity raised.
Sixth Street received warrants to buy up to 200,000 common shares at $0.01, plus 125,000 per monthly extension.
Proceeds used for working capital and general corporate purposes; Board evaluating strategic alternatives.

item 1.01 item 3.02 item 3.03 item 5.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.